Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly’s Intended Successor To Zyprexa Faces Uncertain Future After Phase III Failure

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Failure to perform better than placebo in the first of two pivotal Phase III trials diminishes chances of success for pomaglumetad methionil, a metabotropic glutamate 2/3 receptor agonist that Lilly hoped to position as a successor to its patent-expired schizophrenia therapy Zyprexa.

Advertisement

Related Content

Cruel Summer: High-Profile Trial Failures Dominate R&D News Flow
Cruel Summer: High-Profile Trial Failures Dominate R&D News Flow
No Big Surprises From Lilly: Management Sticks To Its Guns On Strategy
Lilly’s mGlu2/3 Agonist Fails In Phase II For Schizophrenia – But So Does Zyprexa

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS005158

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel